A Phase 4 interventional study of Estradiol/DRSP (Angeliq, BAY86-4891) in Postmenopause, sponsored by Bayer. Completed. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2008-12-12.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms.
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Estradiol/DRSP (Angeliq, BAY86-4891)
Drug pages: Estradiol · Drospirenone
1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
The relative change in the frequency of hot flushes
Time frame: At baseline, week 4, 8, 12
The change in intensity of hot flushes
Time frame: At baseline, week 4, 8, 12
The relative change in frequency of hot flushes
Time frame: At baseline, week 4, 8
The change in intensity of hot flushes
Time frame: At baseline, week 4, 8
The proportions of subjects with urogenital symptoms
Time frame: At baseline, week 4, 8, 12
Bleeding pattern
Time frame: At baseline, week 4, 8, 12
Adverse events collection
Time frame: Collection of AE throughout the study period
No study locations are listed for this record.
The record gives a start of Sep 2005 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Drospirenone